Joan Albanell
Universitat Pompeu Fabra(ES)Pompeu Fabra University(ES)Instituto de Salud Carlos III(ES)Centre for Biomedical Network Research on Rare Diseases(ES)Hospital Del Mar(ES)Municipal Institute for Medical Research(ES)Hospital del Mar Research Institute(ES)Centro de Investigación Biomédica en Red de Cáncer(ES)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Cancer Cells and Metastasis, Breast Cancer Treatment Studies, Lung Cancer Treatments and Mutations
Most-Cited Works
- Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.(1998)
- → Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types(2002)831 cited
- Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.(2001)
- → A SNAIL1–SMAD3/4 transcriptional repressor complex promotes TGF-β mediated epithelial–mesenchymal transition(2009)634 cited
- → Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations(2018)545 cited
- → Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer(2012)500 cited
- → Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer